Human Granulocyte Stimulating Factor Injection may be used once daily with monitoring of blood counts and discontinued when neutrophils reach 0.5 x 10^9/L. If using long acting, once a week.
Human Granulocyte Stimulating Factor Injection can be used to promote an increase in neutrophil count after bone marrow transplantation, as well as for neutropenia caused by cancer chemotherapy, and neutropenia caused by myelodysplastic syndromes and aplastic anemia.
When the patient’s condition meets the indications of this drug, human granulocyte stimulating factor injection should be used once a day, the specific dosage should depend on the patient’s condition, and dynamic monitoring of blood routine, until the neutrophil reaches 0.5 x 10^9 / L to stop the drug, and observe the condition. If using long-acting, once a week.
Human Granulocyte Stimulating Factor Injection should not be used in people who are allergic to this drug, people with severe cardiac, hepatic and renal dysfunction, and patients with myeloid leukemia who do not have a significant reduction of naïve cells in the bone marrow. Use may cause adverse reactions such as bone pain, fever, back pain, and abnormal liver function.
Human Granulocyte Stimulating Factor Injection should be used under medical supervision. If you feel unwell, you should seek medical advice.